Market Exclusive

Analyst Downgrades – NASDAQ:ESPR – Esperion Therapeutics (NASDAQ:ESPR) Stock Gets Downgraded By JPMorgan Chase from Neutral to Underweight

Analyst Ratings For NASDAQ:ESPR – Esperion Therapeutics (NASDAQ:ESPR)

Today, NASDAQ:ESPR – Esperion Therapeutics (NASDAQ:ESPR) stock was downgraded by JPMorgan Chase from Neutral to Underweight with a price target of $41.00.

Some recent analyst ratings include

Recent Insider Trading Activity For NASDAQ:ESPR – Esperion Therapeutics (NASDAQ:ESPR)
NASDAQ:ESPR – Esperion Therapeutics (NASDAQ:ESPR) has insider ownership of 32.50% and institutional ownership of 90.96%.

Recent Trading Activity for NASDAQ:ESPR – Esperion Therapeutics (NASDAQ:ESPR)
Shares of NASDAQ:ESPR – Esperion Therapeutics closed the previous trading session at 39.83 down -5.92 12.94% with 44.599998474121094 shares trading hands.

Exit mobile version